BioCentury | Dec 9, 2020
Deals

Reneo to start pivotal trial in mitochondrial diseases, build orphan pipeline with Novo, Abingworth-led $95M series B

...Lundbeckfonden Ventures, as well as RiverVest.TARGETSPPARδ - Peroxisome proliferation activated receptor δ Paul Bonanos REN001, HPP593 Reneo Pharmaceuticals Inc. Peroxisome proliferation activated receptor (PPAR) delta...
BioCentury | Aug 28, 2020
Product Development

Data Bytes: NASH pipeline still full despite high-profile setbacks

...“Inventiva vs. Intercept in NASH”).TARGETSFXR (NR1H4) – Farnesoid X receptorPPAR ɑ –  Peroxisome proliferation activated receptor alphaPPAR ƍ –  Peroxisome proliferation activated receptor delta Amanda...
...Micklus Intercept Pharmaceuticals Inc. Genfit S.A. Novartis AG Pfizer Inc. Inventiva S.A. Farnesoid X receptor (FXR) (NR1H4) Peroxisome proliferation activated receptor (PPAR) alpha Peroxisome proliferation activated receptor (PPAR) delta NASH pipeline...
BioCentury | May 13, 2020
Product Development

May 12 Quick Takes: Skyhawk, Merck expand deal; plus Sanofi’s Sarclisa and clinical updates drive gains for Gamida, CymaBay

...cord blood transplant. BioCentury Staff Sarclisa, isatuximab-irfc (SAR650984) Omidubicel (NiCord) Merck & Co. Inc. Skyhawk Therapeutics Inc. CymaBay Therapeutics Inc. Sanofi Gamida Cell Ltd. Peroxisome proliferation activated receptor (PPAR) delta...
BioCentury | May 12, 2020
Product Development

May 11 Quick Takes: Genfit’s elafibranor misses in NASH Phase III; plus AstraZeneca, Merck, Protalix and TolerogenixX

...study in systemic lupus erythematosus patients in 2021. Targets PARP - Poly(ADP-ribose) polymerase PPARδ - Peroxisome proliferation activated receptor delta...
...galactosidase, pegunigalsidase alfa (CHF 6657; PRX-102) elafibranor (GFT505) AstraZeneca plc Merck & Co. Inc. Protalix BioTherapeutics Inc. Genfit S.A. Alpha galactosidase A Peroxisome proliferation activated receptor (PPAR) delta TolerogenixX...
BioCentury | Feb 21, 2020
Product Development

Feb. 20 Product Development Quick Takes: Priority Review puts BioMarin on track to score first hemophilia gene therapy approval in U.S.; plus Gilead-CDC, Genfit

...passed re-inspection by the agency. Targets PPARα - Peroxisome proliferation activated receptor alpha PPARδ - Peroxisome proliferation activated receptor delta...
BioCentury | Jan 11, 2020
Finance

Why buysiders say 2020 could be the year of the CNS

...CD279) - Programmed cell death 1 PPARα - Peroxisome proliferation activated receptor alpha PPARδ - Peroxisome proliferation activated receptor delta...
BioCentury | Nov 25, 2019
Clinical News

Months after NASH failure, more woes for CymaBay's lead product on safety

...protein-coupled receptor 120; PPARδ - Peroxisome proliferation activated receptor δ Sandi Wong, Staff Writer seladelpar (MBX-8025) CymaBay Therapeutics Inc. Peroxisome proliferation activated receptor (PPAR) delta primary...
BioCentury | May 20, 2019
Emerging Company Profile

Reneo: Small molecules for rare mitochondrial diseases

...High Point, N.C. Targets PPARδ - Peroxisome proliferation activated receptor δ Chris Lieu, Staff Writer Reneo Pharmaceuticals Inc. Peroxisome proliferation activated receptor (PPAR) delta Mitochondrial...
BioCentury | Apr 5, 2019
Targets & Mechanisms

Breaking up Hippo to tame proliferation

...1 (MAP2K1) (MEK1) MAP kinase kinase 2 (MAP2K2) (MEK2) Neurofibromin 2 (NF2) (Merlin) Peroxisome proliferation activated receptor (PPAR) alpha Peroxisome proliferation activated receptor (PPAR) delta Peroxisome...
BioCentury | Feb 23, 2019
Product Development

Benchmarks for NASH

...all-cause mortality Top-line data 2020 Genfit S.A. (Euronext:GNFT) Elafibranor Peroxisome proliferation activated receptor (PPAR) alpha; PPAR delta...
...CCR2) (CD192) CC chemokine receptor 5 (CCR5) (CD195) Farnesoid X receptor (FXR) (NR1H4) Peroxisome proliferation activated receptor (PPAR) alpha Peroxisome proliferation activated receptor (PPAR) delta...
Items per page:
1 - 10 of 89